Evidence map›Paper›PMID 40035422›Full record

ArticleCancer reports (Hoboken, N.J.)2025

First-Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR: A Case Report.

Zaiyong Jin, Fei Zhou, Zhuo Wang, Hongji Li

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zaiyong JinDepartment of Hepatological Surgery, Jilin City Central Hospital, Jilin, China.
Fei ZhouMedical Image Central, Jilin City Central Hospital, Jilin, China.
Zhuo WangDepartment of Abdominal Imaging Diagnostic, Jilin City Central Hospital, Jilin, China.
Hongji LiDepartment of Traditional and Western Oncology, Jilin City Central Hospital, Jilin, China.ORCID 0009-0002-8176-2420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) remains a significant global health burden, with unmet clinical needs despite the availability of multiple therapeutic options. CASE: We present the case of an 85-year-old male diagnosed with HCC and bilateral lung metastases following hepatectomy. The patient responded favorably to treatment with icaritin and thalidomide, which resulted in a reduction in alpha-fetoprotein (AFP) levels and tumor size. This treatment achieved partial remission, with a progression-free survival (PFS) of 24 months and an overall survival (OS) of 33 months. Unfortunately, the patient ultimately passed away due to a cerebral infarction unrelated to cancer progression.

conclusionThis case underscores the potential of icaritin as a therapeutic option for HCC patients with compromised health status. The combination of icaritin and thalidomide demonstrated promising efficacy in this real-world scenario. Multidisciplinary combination treatment strategies incorporating icaritin merit further exploration, given its immunomodulatory effects and favorable safety profile.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularFlavonoidsLiver NeoplasmsLung NeoplasmsThalidomideAged, 80 and overalpha-FetoproteinsFatal OutcomeHepatectomyHumansMalealpha-FetoproteinsFlavonoidsicaritinThalidomidecombination therapyicaritinlate‐stage hepatocellular carcinomapartial remissionthalidomide (TLD)

Identifiers

PMID40035422
PMCPMC11877328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.